Diabetic Cataract Surgery: Special Considerations

Diabetic Cataract Surgery: Special Considerations

Every cataract surgeon working in India, Southeast Asia or the Middle East knows the pattern: the 54-year-old with grade 3 nuclear sclerosis, a fast-evolving posterior subcapsular plaque, and an HbA1c of 9.2%. Diabetes accelerates lens opacification by roughly a decade, and in many of our markets diabetics now make up a third or more of the elective phaco list. The operation itself may look routine. The physiology is not. Diabetic eyes have fragile endothelium, unstable blood-retinal barriers, small pupils, friable iris vessels and retinas that may be one VEGF surge away from macular oedema. Outcomes are still generally good — but they are good when the surgeon plans for diabetes at every step, not merely acknowledges it in the case notes.

This article walks through the perioperative decisions that matter most: preoperative retinal work-up and timing, intraoperative modifications, IOL and viscoelastic selection, macular oedema prophylaxis, and postoperative surveillance. The aim is practical — what to change on Monday morning.

Why Diabetic Eyes Behave Differently Under the Phaco Tip

The metabolic context

Chronic hyperglycaemia drives sorbitol accumulation in lens fibres, accelerates glycation of lens proteins, and produces the characteristic early posterior subcapsular and cortical changes. But the lens is not the vulnerable tissue during surgery — the cornea and retina are. Diabetic corneas show reduced endothelial reserve in many studies, slower epithelial healing, and a higher incidence of persistent postoperative epithelial defects. Diabetic retinas have compromised endothelial tight junctions; the blood-retinal barrier that a non-diabetic eye reseals within weeks of surgery may leak for months in a diabetic eye, particularly if there is pre-existing diabetic retinopathy (DR).

Iris behaviour also differs. Poor pupillary dilation despite a full mydriatic cocktail is common, reflecting autonomic neuropathy and iris neovascular or glycation changes. A 5 mm pupil that would be an inconvenience in a routine case becomes a genuine complication multiplier in a diabetic eye with a dense brunescent nucleus.

What the outcome literature shows

The outcome data are reassuring but conditional. In a prospective series of 150 diabetic patients undergoing small-incision cataract surgery, Krepler and colleagues reported meaningful visual gains in the great majority, but demonstrated that eyes with preoperative DR — particularly proliferative disease — had significantly worse final acuity and a higher rate of retinopathy progression than non-diabetic controls (Krepler et al., Graefe's Archive for Clinical and Experimental Ophthalmology, 2002). The message: the surgery succeeds; the retina determines the ceiling.

Preoperative Assessment: Beyond the Lens

Document the retina before you touch the lens

Two questions must be answered before listing: does this patient have DR, and is the macula dry? A dilated fundus examination is the minimum standard; where the fundus view is limited by lens density, document B-scan ultrasonography to exclude tractional pathology, and plan OCT immediately after media clearance.

Where the macula is visible, preoperative OCT has changed practice. Subclinical diabetic macular oedema (DME) that is invisible on biomicroscopy shows up readily on OCT, and operating on an undetected oedematous macula invites a disappointing outcome and an unhappy patient. Kim and colleagues, using OCT in diabetic eyes undergoing cataract surgery, found that a substantial proportion of patients developed or worsened macular thickening postoperatively — and that pre-existing retinopathy severity was the strongest predictor (Kim et al., Ophthalmology, 2007).

If centre-involving DME or high-risk PDR is present, treat the retina first. Intravitreal anti-VEGF therapy two to four weeks before cataract surgery — or at the time of surgery — and completion of panretinal photocoagulation before lens removal are both defensible sequences; the priority is that the retina is stabilised before the intraocular inflammation of surgery is added to the equation.

Glycaemic control and timing

There is no universal HbA1c cut-off that cancels surgery, and rigid thresholds delay sight-restoring treatment for the patients who need it most. Reasonable practice: document recent glycaemic control, involve the treating physician when HbA1c exceeds roughly 9–10%, and schedule diabetics early in the operative day to minimise fasting disruption. Perioperative hypoglycaemia in a fasting diabetic is a real anaesthetic risk; perioperative hyperglycaemia impairs wound healing and may amplify inflammatory responses. Coordinate with your anaesthetist and keep the interval between fasting and surgery short.

Set expectations in the counselling chair

Diabetic patients need to hear two things before consent: their final vision depends on their retina as much as on the surgery, and they may need additional retinal treatment after the operation. Documenting this conversation protects the patient-surgeon relationship when an OCT at week six shows oedema that was always a possibility.

Intraoperative Modifications

Pupil management

Plan for the small pupil rather than reacting to it. Options in ascending order of commitment: high-viscosity cohesive OVD for viscomydriasis, pupil expansion rings or iris hooks, and — increasingly popular in high-volume settings — mechanical pupil expansion devices that preserve the iris for future glaucoma or retinal surgery. Avoid aggressive iris stretching on a diabetic iris; bleeding and postoperative inflammation are disproportionate. A well-stocked pupil expansion and surgical consumables drawer is cheap insurance.

Endothelial protection and OVD strategy

The diabetic endothelium tolerates ultrasound energy and turbulence poorly. Minimise cumulative dissipated energy: use torsional or transversal phaco modalities, keep the phaco tip in the deep chamber, and consider a soft-shell technique — dispersive OVD coating the endothelium beneath a cohesive core — for brunescent lenses. Choice of ophthalmic viscosurgical device genuinely matters here: a high-molecular-weight dispersive agent provides sustained endothelial coating through the case, while a cohesive agent simplifies removal at the end. In diabetic eyes, many surgeons use both. As with any intraocular device, consult the product IFU for indications and handling.

Capsule and rupture contingency

Diabetic lenses deserve respect for posterior capsular rupture risk: brunescent diabetic nuclei are common, anterior capsules can be fibrotic and friable, and zonular status is occasionally marginal in long-standing diabetics. A capsular tear in a diabetic eye is doubly expensive — sulcus fixation restricts future retinal access, and dropped nuclear fragments demand early vitrectomy in an eye that tolerates additional surgery poorly. Keep a capsular tension ring on the tray for any zonular doubt, and lower your threshold for converting to a planned extracapsular extraction in rock-hard lenses rather than chasing the nucleus with ultrasound.

IOL selection in diabetic eyes

Three principles govern IOL choice:

1. Biocompatibility and optics. Single-piece hydrophobic acrylic lenses in the capsular bag are the default. Sharp posterior optic edges reduce posterior capsule opacification — valuable because YAG capsulotomy in a diabetic eye carries a small but real risk of triggering or worsening DME, and you want to defer that laser as long as possible.
2. Respect future retinal access. Avoid silicone IOLs in any eye that may need vitreoretinal surgery with silicone oil endotamponade — silicone oil condenses irreversibly on silicone lenses. Consider larger-optic designs where peripheral retinal visualisation for future laser or vitrectomy matters.
3. Be conservative with premium optics. Multifocal and EDOF lenses split and stretch light; on a retina with compromised contrast sensitivity from DR — current or future — the trade is usually poor. A quality monofocal or, in stable eyes with no maculopathy, a toric monofocal serves most diabetic patients best. If DR progresses after implantation of a multifocal, you own a difficult explant conversation.

Our intraocular lens portfolio, including hydrophobic acrylic and toric platforms, is CE Marked and licensed by FDA India (CDSCO); regulatory status varies by country, and the product IFU governs indications in your market.

Macular Oedema: Prevention and Perioperative Strategy

Postoperative macular oedema is the single most common cause of a dissatisfied diabetic cataract patient with a technically perfect operation. Distinguish two entities: pseudophakic (Irvine-Gass) oedema, which can occur in any eye but is more frequent and more persistent in diabetics, and true DME reactivation driven by surgical inflammation on a compromised vasculature.

A practical prophylaxis framework:

• No retinopathy or mild NPDR: standard postoperative topical steroid plus an NSAID for 4–6 weeks. Topical NSAID prophylaxis reduces the incidence of angiographic and clinical cystoid macular oedema and is particularly worth insisting on in diabetics.
• Moderate-to-severe NPDR or prior DME: add a perioperative intravitreal anti-VEGF agent, typically at or shortly before surgery, and extend topical NSAID coverage.
• Tractional components or vitreomacular interface disease: coordinate with your retina colleague; combined or staged phacovitrectomy may be the right operation.

Steroid choice matters in diabetics, who are over-represented among steroid responders. Where a potent topical steroid is indicated, define the taper and check pressure at two to three weeks. The ophthalmic pharmaceuticals range covers perioperative antibiotic, steroid and NSAID needs; consult each product IFU for dosing and contraindications.

Postoperative Care and Retinopathy Surveillance

The diabetic postoperative schedule should be tighter than routine:

• Day 1 and week 1: wound, IOP and inflammation as usual. Watch for fibrinous anterior chamber reactions — more common in diabetics — and treat aggressively.
• Week 4–6: OCT the macula, even when acuity is good. Early DME is treatable; late DME after months of subtle thickening is a chronic disease.
• Month 3: dilated fundus examination to grade retinopathy. Krepler and colleagues documented progression of DR after cataract surgery in a meaningful minority of eyes (Krepler et al., 2002), and Javadi and Zarei-Ghanavati, reviewing cataract management in diabetic patients, emphasise that cataract surgery can unmask or accelerate retinopathy — making structured postoperative retinal review a core part of the operation, not an optional add-on (Javadi and Zarei-Ghanavati, Journal of Ophthalmic and Vision Research, 2008).

Sustained glycaemic control remains the patient's most powerful intervention; say so at discharge and say it again at month three. Surgery clears the window — diabetes management determines the view.

Practical Takeaways

• OCT the macula before listing whenever the fundus is visible; B-scan when it is not.
• Stabilise DME and complete PRP before elective cataract surgery; treat the retina first, the lens second.
• Expect the small pupil; stage expansion devices rather than improvising.
• Protect the endothelium deliberately: dispersive coating, low-energy phaco, deep-chamber technique.
• Hydrophobic acrylic monofocal or toric monofocal in the bag for most; no silicone lenses in eyes with retinal surgical futures; be cautious with multifocal optics.
• Extend topical NSAID prophylaxis; add perioperative anti-VEGF for moderate NPDR or worse.
• OCT at 4–6 weeks and dilated retinal review at 3 months for every diabetic patient.

Frequently Asked Questions

Is cataract surgery safe for diabetic patients?

Yes. Modern phacoemulsification is safe and effective in diabetic eyes, with the great majority of patients gaining useful vision. Outcomes depend heavily on pre-existing diabetic retinopathy severity, so preoperative retinal assessment, macular OCT and structured postoperative surveillance are essential parts of safe care.

What is the best IOL for a diabetic patient?

A single-piece hydrophobic acrylic monofocal lens in the capsular bag suits most diabetic eyes. Add a toric design for significant regular astigmatism in stable retinas. Avoid silicone lenses if future vitreoretinal surgery is likely, and use multifocal IOLs cautiously because diabetic retinopathy reduces contrast sensitivity.

Should diabetic retinopathy be treated before cataract surgery?

Significant retinopathy should be stabilised first. Centre-involving macular oedema is treated with anti-VEGF injections before or at surgery, and proliferative disease should receive panretinal photocoagulation before lens removal. Operating on an untreated, actively leaking retina markedly worsens visual outcomes.

Does cataract surgery worsen diabetic retinopathy?

It can. Postoperative inflammation accelerates retinopathy progression in a minority of eyes, and macular oedema risk rises with pre-existing retinopathy severity. Perioperative anti-VEGF therapy, extended topical NSAID prophylaxis and scheduled OCT follow-up at four to six weeks substantially reduce this risk.

How should blood sugar be managed around cataract surgery?

Document recent glycaemic control and involve the treating physician when control is poor. Schedule diabetic patients early in the day to shorten fasting, coordinate insulin or oral hypoglycaemic adjustment with the anaesthetist, and avoid both perioperative hypoglycaemia and sustained hyperglycaemia, which impairs wound healing.

---

Plan your diabetic cataract workflows with us. Request a product sample of our hydrophobic acrylic IOLs and viscoelastic systems, or download the relevant IFU for full handling and indication details. Distributors serving high-diabetes-prevalence markets can explore partnership terms.

---

This article is for educational purposes and is intended for healthcare professionals. It does not constitute medical advice, diagnosis or treatment recommendations for individual patients. Clinical decisions remain the responsibility of the treating surgeon. Oculentis Medical products referenced are CE Marked and licensed by FDA India (CDSCO); regulatory status varies by country. Always consult the product Instructions for Use (IFU) before use.

Medically reviewed by the Oculentis Medical Editorial Team.